TY - JOUR
T1 - A Randomized Trial to Compare the Safety, Tolerability, and Effectiveness of 3 Antimalarial Regimens for the Prevention of Malaria in Nigerian Patients with Sickle Cell Disease
AU - Olaosebikan, Rasaq
AU - Ernest, Kolade
AU - Bojang, Kalifa
AU - Mokuolu, Olugbenga
AU - Rehman, Andrea M.
AU - Affara, Muna
AU - Nwakanma, Davis
AU - Kiechel, Jean Rend
AU - Ogunkunle, Taofik
AU - Olagunju, Tope
AU - Murtala, Rukayat
AU - Omefe, Peter
AU - Lambe, Tosin
AU - Bello, Surajudeen
AU - Ibrahim, Olayinka
AU - Olorunsola, Benedict
AU - Ojuawo, Ayotade
AU - Greenwood, Brian
AU - Milligan, Paul
N1 - Publisher Copyright:
© 2015 The Author.
PY - 2015/8/15
Y1 - 2015/8/15
N2 - Background. Malaria prophylaxis is recommended for persons with sickle cell disease (SCD), but the value of this has been questioned. The aim of this study was to find out whether intermittent preventive treatment (IPT) with a fixed-dose combination of mefloquine-artesunate (MQAS) or sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) was more effective than daily proguanil for malaria prevention in subjects with SCD. Methods. Patients with SCD were randomized to receive daily treatment with proguanil or IPT with either MQAS or SPAQ once every 2 months at routine clinic visits. Patients were followed up for 14 months. Findings. A total of 270 patients with SCD were studied, with 90 in each group. Adherence to the IPT regimens was excellent, but 57% of patients took <75% of their daily doses of proguanil. IPT was well tolerated; the most common side effects were vomiting and abdominal pain. Protective efficacy against malaria, compared with daily proguanil, was 61% (95% confidence interval, 3%-84%) for MQAS and 36% (40%-70%) for SPAQ. There were fewer outpatient illness episodes in children who received IPT than those who received proguanil. Conclusions. IPT with MQAS administered to patients with SCD during routine clinic visits was well tolerated and more effective in preventing malaria than daily prophylaxis with proguanil.
AB - Background. Malaria prophylaxis is recommended for persons with sickle cell disease (SCD), but the value of this has been questioned. The aim of this study was to find out whether intermittent preventive treatment (IPT) with a fixed-dose combination of mefloquine-artesunate (MQAS) or sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) was more effective than daily proguanil for malaria prevention in subjects with SCD. Methods. Patients with SCD were randomized to receive daily treatment with proguanil or IPT with either MQAS or SPAQ once every 2 months at routine clinic visits. Patients were followed up for 14 months. Findings. A total of 270 patients with SCD were studied, with 90 in each group. Adherence to the IPT regimens was excellent, but 57% of patients took <75% of their daily doses of proguanil. IPT was well tolerated; the most common side effects were vomiting and abdominal pain. Protective efficacy against malaria, compared with daily proguanil, was 61% (95% confidence interval, 3%-84%) for MQAS and 36% (40%-70%) for SPAQ. There were fewer outpatient illness episodes in children who received IPT than those who received proguanil. Conclusions. IPT with MQAS administered to patients with SCD during routine clinic visits was well tolerated and more effective in preventing malaria than daily prophylaxis with proguanil.
UR - http://www.scopus.com/inward/record.url?scp=84939636387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939636387&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiv093
DO - 10.1093/infdis/jiv093
M3 - Article
C2 - 25701866
AN - SCOPUS:84939636387
SN - 0022-1899
VL - 212
SP - 617
EP - 625
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 4
ER -
